Search hospitals > New Jersey > Livingston
Saint Barnabas Medical Center
Claim this profileLivingston, New Jersey 07039
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Tumors
Conducts research for Kidney Transplant
Conducts research for Leukemia
208 reported clinical trials
31 medical researchers
Summary
Saint Barnabas Medical Center is a medical facility located in Livingston, New Jersey. This center is recognized for care of Breast Cancer, Cancer, Tumors, Kidney Transplant, Leukemia and other specialties. Saint Barnabas Medical Center is involved with conducting 208 clinical trials across 328 conditions. There are 31 research doctors associated with this hospital, such as Howard S. Hochster, Missak Haigentz, MD, Eugenia Girda, MD, and Patrick M. Boland.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 positive
HER2 negative
2Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Howard S. HochsterRutgers Cancer Institute of New Jersey4 years of reported clinical research
Expert in Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
37 drugs studied
Missak Haigentz, MDRutgers Cancer Institute of New Jersey3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
14 reported clinical trials
23 drugs studied
Eugenia Girda, MDRutgers Cancer Institute of New Jersey4 years of reported clinical research
Studies Cancer
Studies Ovarian Cancer
14 reported clinical trials
29 drugs studied
Patrick M. BolandRutgers Cancer Institute of New Jersey4 years of reported clinical research
Studies Colon Cancer
Studies Colorectal Cancer
9 reported clinical trials
18 drugs studied
Clinical Trials running at Saint Barnabas Medical Center
Breast Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Squamous Cell Carcinoma
Gallbladder Cancer
Colon Cancer
Cancer
Oral Squamous Cell Carcinoma
Pancreatic Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Saint Barnabas Medical Center?
Saint Barnabas Medical Center is a medical facility located in Livingston, New Jersey. This center is recognized for care of Breast Cancer, Cancer, Tumors, Kidney Transplant, Leukemia and other specialties. Saint Barnabas Medical Center is involved with conducting 208 clinical trials across 328 conditions. There are 31 research doctors associated with this hospital, such as Howard S. Hochster, Missak Haigentz, MD, Eugenia Girda, MD, and Patrick M. Boland.